New stock news | Haixi Pharma submits a second application to the Hong Kong Stock Exchange to create a diversified product portfolio and pipeline with a dual-track approach.

According to the app of Securities Times, it was revealed by the Hong Kong Stock Exchange on August 6th that Fujian Haixi Pharmaceutical Research and Development Co., Ltd. (hereinafter referred to as Haixi Pharmaceutical) has submitted an application to the main board of the Hong Kong Stock Exchange, with Huatai International and CICC acting as its joint sponsors. The company had previously submitted an application to the Hong Kong Stock Exchange on January 3rd.